Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Launched by UNIVERSITY OF CHICAGO · Dec 6, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat men with prostate cancer by using a special imaging technique called MRI. The goal is to reduce the amount of radiation given to areas of the prostate that don’t have cancer while increasing the radiation to the cancerous spots. By doing this, the researchers hope to improve treatment outcomes while also preserving the patient’s quality of life.

To participate in this trial, men must be at least 18 years old and have been diagnosed with a specific type of prostate cancer that can be seen on an MRI. They should not have received any previous treatments for prostate cancer, such as surgery or chemotherapy, and should not have spread cancer outside of the prostate area. If eligible, participants can expect to undergo MRI scans and radiation treatment as outlined in the study. It’s important to note that individuals with certain health conditions or those who cannot safely undergo MRI may not be able to participate. This trial is currently recruiting participants, so interested individuals should consult with their healthcare provider for more details.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Adult (≥ 18 years old) male patients with an ECOG Performance Status 0-2
• • Histologically-confirmed, MRI-visible prostate adenocarcinoma with NCCN intermediate- or high-risk disease1 without extra-pelvic metastasis.
• Exclusion Criteria:
• • Distant metastases
• • Prior active treatment for prostate cancer including radical prostatectomy, high-intensity focused ultrasound (HIFU), cryosurgery, ADT, or cytotoxic chemotherapy for treatment of prostate cancer. Patients with prostate cancer on active surveillance prior to the study are not excluded if they have not received active treatment.
• • Prior pelvic radiotherapy including brachytherapy.
• • Additional active concurrent malignancies (except localized cutaneous squamous or basal cell carcinomas).
• • Comorbid conditions that, in the opinion of the treating radiation oncologist, preclude the patient from safely receiving the protocol-specified treatment including RT and/or ADT.
• • Patients with contraindications to MRI including patients with ferromagnetic materials in their body (e.g. bioimplants, surgical hardware, shrapnel), patients who are unable to receive contrast due to history of allergy or impaired renal function (glomerular filtration rate \< 30 mil/min), and patients unable to tolerate MRI for other reasons (e.g. significant claustrophobia).
• • Patients for whom hydrogel or hyaluronic acid spacer will be placed.
• • Patients incapable of giving informed consent.
• • Patients who are unable to adhere to the experimental protocols for any reason.